Synergistic Effect of 5-Aza-2′-Deoxycytidine and Genistein in Combination Against Leukemia

Authors: Raynal, Noël J.-M.; Charbonneau, Michel; Momparler, Louise F.; Momparler, Richard L.

Source: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Volume 17, Number 5, May 2008 , pp. 223-230(8)

Publisher: Cognizant Communication Corporation

Buy & download fulltext article:

OR

Price: $79.00 plus tax (Refund Policy)

Abstract:

5-Aza-2′-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation, is an effective agent for the treatment of leukemia. The aim of this study was to investigate the antileukemic activity of this epigenetic agent in combination with genistein, a nontoxic isoflavone with chemopreventive activity. The combined treatment produced a synergistic loss of clonogenicity in human myeloid (HL-60) and lymphoid (MOLT-3) leukemic cell lines. Genistein alone showed a significant antileukemic activity against murine 5-AZA-CdR-resistant cells, and this effect was enhanced when used in combination with 5-AZA-CdR. The combined treatment also produced a synergistic increase in life span of mice with L1210 leukemia. These results suggest that genistein may have the potential to increase the clinical efficacy of 5-AZA-CdR for the treatment of leukemia.

Keywords: 5-Aza-2′-deoxycytidine; Chemotherapy; Drug resistance; Epigenetic; Genistein; Leukemia

Document Type: Research Article

DOI: http://dx.doi.org/10.3727/096504008786111356

Publication date: May 1, 2008

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page